Dexrazoxane 10 mg for every 1 mg of doxorubicin. Administer as a slow injection or rapid infusion over 15-30 minutes.
Dexrazoxane (DEX) selectively blocks the development of irreversible diffuse myocardial toxicity induced by anthracyclines and related antitumor agents, such as mitoxantrone (MTX).
HERCEPTIN & CARDIOTOXICITY
The incidence of cardiac dysfunction was highly dependent on prior or concurrent doxorubicin exposure. For patients with minimal prior anthracycline exposure, the risk of cardiac dysfunction is 1%. For patients with more extensive prior doxorubicin exposure, the risk of cardiac dysfunction is 7% for trastuzumab monotherapy and 12% for trastuzumab + taxol. For patients treated with trastuzumab concurrently with doxorubicin, the risk of cardiac dysfunction is 29%.
REF= (REVIEW) Semin Oncol 28(1Suppl 3):20, 2001